We find that a lot of them have very significant cancer that needs to be treated but wouldn't have been treated unless we had done this biopsy.

A lot of patients are being treated inappropriately with the wrong therapies because they're either under-diagnosed or over-diagnosed.

It's like playing Battleship with the prostate. Every hole that we have has a coordinate, and we can place the needle through that. We have a picture that overlays and shows us the prostate and where that biopsy's being taken from. Then, we can basically look at the picture when we get a positive biopsy back and see exactly where the cancer is in the gland.

Unfortunately, we're finding that [the TRUS biopsy] is really not very effective at all. When you look at the statistics of a normal size gland the chances of actually finding that tumor are about 15 percent. So, 85 percent of patients by that biopsy method may be missing their cancer.

Montana's cancer issues are different from cancer issues in New York. That's why each state needs its own plan. The plans open the way for improved communication about cancer, too. That's important because areas like Montana and west Texas have similarities due to sparse population.

For our cervical cancer vaccine we pursued the objective of inducing a strong immune response and protection that lasts. We are encouraged by a sustained enhanced antibody response we saw with an HPV vaccine formulated with our novel adjuvant.